Questcor upgraded to Buy from Hold at Jefferies Jefferies upgraded Questcor citing valuation and its channel checks that indicated potentially less risk for the company's Acthar sales in nephrotic syndrome. The firm raised its price target for shares to $28 from $24. Note Jefferies downgraded Questcor to Hold on September 20.
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.